Susquehanna Fundamental Investments LLC Takes Position in Kenvue Inc. (NYSE:KVUE)

Susquehanna Fundamental Investments LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 239,681 shares of the company's stock, valued at approximately $5,117,000.

A number of other hedge funds have also modified their holdings of the business. Kiley Juergens Wealth Management LLC boosted its position in shares of Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after buying an additional 500 shares during the period. Principle Wealth Partners LLC boosted its holdings in Kenvue by 3.7% during the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after acquiring an additional 500 shares during the period. White Pine Capital LLC grew its position in Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after acquiring an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after purchasing an additional 568 shares during the period. Finally, SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.1 %

Shares of Kenvue stock traded up $0.02 during trading hours on Friday, hitting $23.98. The company had a trading volume of 14,097,083 shares, compared to its average volume of 17,054,515. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a market cap of $46.01 billion, a P/E ratio of 45.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company's 50-day moving average is $23.08 and its two-hundred day moving average is $22.49.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.42%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio is presently 154.72%.

Analyst Ratings Changes

A number of brokerages recently weighed in on KVUE. Redburn Atlantic started coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective on the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Finally, Citigroup upped their price target on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.